Back to Browse Journals » ClinicoEconomics and Outcomes Research » Volume 4

Health status, hospitalizations, day procedures, and physician costs associated with body mass index (BMI) levels in Ontario, Canada

Authors Tarride JE, Haq M, Taylor VH, Sharma AM, Nakhai-Pour HR,  O'Reilly D, Xie F, Dolovich L, Goeree R

Published Date January 2012 Volume 2012:4 Pages 21—30

DOI http://dx.doi.org/10.2147/CEOR.S24192

Received 13 July 2011, Accepted 14 October 2011, Published 24 January 2012

Jean-Eric Tarride1,2, Mahbubul Haq1, Valerie H Taylor3, Arya M Sharma4, Hamid Reza Nakhai-Pour1, Daria O’Reilly1,2, Feng Xie1,2, Lisa Dolovich2,5,6, Ron Goeree1,2
1Programs for Assessment of Technology in Health (PATH) Research Institute, St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada; 2Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada; 3Department of Psychiatry, University of Toronto, Ontario, Canada; 4Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; 5Centre for Evaluation of Medicines, St Joseph’s Healthcare Hamilton, Hamilton, Ontario, Canada; 6Department of Family Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

Background: Obesity is today’s principal neglected public health problem, as a rising proportion of adults will succumb to the medical complications of obesity. However, little is known about the burden of obesity in adults living in Ontario.
Objectives: To present an overview of the human and economic burden associated with BMI categories in Ontario, Canada, in terms of socio-demographics, comorbidities, health-related quality of life (HRQoL) and costs associated with hospitalization, same day procedures and physician visits.
Methods: The records of all Ontarians who participated in the Canadian Community Health Survey (CCHS), cycle 1.1 and provided consent to data linkage were linked to three administrative databases. Socio-demographic variables, medical characteristics, HRQoL, one year hospitalization, day procedure and physician costs were described per BMI category. Regression analyses were conducted to identify predictors of medical characteristics, HRQoL and costs.
Results: More than 50% of adult participants were either overweight or obese in 2000/2001. Obese adults, and to a lesser extent overweight adults, were more likely to report physician-diagnosed comorbid conditions, to use medications, and to have a lower HRQoL. After covariate adjustment, the hospitalization and physician costs were respectively 40% and 22% higher among obese and overweight adults than among normal-weight adults. No statistical cost differences were observed between normal and underweight individuals or between normal and overweight individuals. HRQoL was significantly lower in underweight and obese adults when compared to normal-weight individuals.
Conclusions: Due to the large human and economic burden associated with under- or excess-weight, policies promoting healthy weight should remain a priority for governments and employers.

Keywords: health-related quality of life, costs, body mass index categories, Ontario

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Readers of this article also read:

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers

Nagelschmitz J, Blunck M, Kraetzschmar J, Ludwig M, Wensing G, Hohlfeld T

Clinical Pharmacology: Advances and Applications 2014, 6:51-59

Published Date: 19 March 2014

Population pharmacokinetics of olprinone in healthy male volunteers

Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H

Clinical Pharmacology: Advances and Applications 2014, 6:43-50

Published Date: 4 March 2014

Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Thavorncharoensap M, Teerawattananon Y, Natanant S, Kulpeng W, Yothasamut J, Werayingyong P

ClinicoEconomics and Outcomes Research 2013, 5:29-36

Published Date: 10 January 2013

Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy

Estevanato LC, Da Silva JR, Falqueiro AM, Mosiniewicz-Szablewska E, Suchocki P, Tedesco AC, Morais PC, Lacava ZG

International Journal of Nanomedicine 2012, 7:5287-5299

Published Date: 5 October 2012

Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy

Schwander B, Ravera S, Giuliani G, Nuijten M, Walzer S

ClinicoEconomics and Outcomes Research 2012, 4:237-243

Published Date: 3 September 2012

Detemir as a once-daily basal insulin in type 2 diabetes

Nelson SE

Clinical Pharmacology: Advances and Applications 2011, 3:27-37

Published Date: 18 August 2011